Gyre Therapeutics Statistics
Total Valuation
GYRE has a market cap or net worth of $819.23 million. The enterprise value is $790.93 million.
Important Dates
The last earnings date was Friday, May 9, 2025, before market open.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GYRE has 90.32 million shares outstanding. The number of shares has increased by 44.36% in one year.
| Current Share Class | 90.32M |
| Shares Outstanding | 90.32M |
| Shares Change (YoY) | +44.36% |
| Shares Change (QoQ) | +18.64% |
| Owned by Insiders (%) | 7.04% |
| Owned by Institutions (%) | 2.91% |
| Float | 19.96M |
Valuation Ratios
The trailing PE ratio is 112.98.
| PE Ratio | 112.98 |
| Forward PE | n/a |
| PS Ratio | 7.74 |
| Forward PS | 27.98 |
| PB Ratio | 11.67 |
| P/TBV Ratio | 13.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 109.08 |
| EV / Sales | 7.86 |
| EV / EBITDA | 65.16 |
| EV / EBIT | 75.82 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.60, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.60 |
| Quick Ratio | 2.65 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.12 |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 12.12% and return on invested capital (ROIC) is 6.69%.
| Return on Equity (ROE) | 12.12% |
| Return on Assets (ROA) | 5.18% |
| Return on Invested Capital (ROIC) | 6.69% |
| Return on Capital Employed (ROCE) | 9.41% |
| Revenue Per Employee | $173,822 |
| Profits Per Employee | $12,523 |
| Employee Count | 579 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 0.59 |
Taxes
In the past 12 months, GYRE has paid $3.68 million in taxes.
| Income Tax | 3.68M |
| Effective Tax Rate | 23.91% |
Stock Price Statistics
The stock price has decreased by -8.84% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -8.84% |
| 50-Day Moving Average | 9.08 |
| 200-Day Moving Average | 11.46 |
| Relative Strength Index (RSI) | 45.78 |
| Average Volume (20 Days) | 337,820 |
Short Selling Information
The latest short interest is 2.48 million, so 2.74% of the outstanding shares have been sold short.
| Short Interest | 2.48M |
| Short Previous Month | 2.37M |
| Short % of Shares Out | 2.74% |
| Short % of Float | 12.40% |
| Short Ratio (days to cover) | 22.82 |
Income Statement
In the last 12 months, GYRE had revenue of $100.64 million and earned $7.25 million in profits. Earnings per share was $0.02.
| Revenue | 100.64M |
| Gross Profit | 96.84M |
| Operating Income | 10.43M |
| Pretax Income | -74.61M |
| Net Income | 7.25M |
| EBITDA | 12.14M |
| EBIT | 10.43M |
| Earnings Per Share (EPS) | $0.02 |
Full Income StatementBalance Sheet
The company has $29.89 million in cash and $1.59 million in debt, giving a net cash position of $28.31 million or $0.31 per share.
| Cash & Cash Equivalents | 29.89M |
| Total Debt | 1.59M |
| Net Cash | 28.31M |
| Net Cash Per Share | $0.31 |
| Equity (Book Value) | 104.30M |
| Book Value Per Share | 0.78 |
| Working Capital | 49.46M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$6.65 million and capital expenditures -$2.21 million, giving a free cash flow of -$8.86 million.
| Operating Cash Flow | -6.65M |
| Capital Expenditures | -2.21M |
| Free Cash Flow | -8.86M |
| FCF Per Share | -$0.10 |
Full Cash Flow StatementMargins
Gross margin is 96.23%, with operating and profit margins of 10.36% and 7.20%.
| Gross Margin | 96.23% |
| Operating Margin | 10.36% |
| Pretax Margin | 15.27% |
| Profit Margin | 7.20% |
| EBITDA Margin | 12.06% |
| EBIT Margin | 10.36% |
| FCF Margin | n/a |